Associated Papers
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.
Cao J et al.
Eclinicalmedicine, 2025
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.
Nagy Á et al.
Journal of Internal Medicine, 2023
Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients.
Shyu JY et al.
Plos One, 2023
Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia.
Arai H et al.
Biomedicines, 2022
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL et al.
Blood Advances, 2021
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia.
Fontana D et al.
Frontiers in Oncology, 2021
Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.
Nagy Á et al.
Genes, 2020
Inactivation of Epigenetic Regulators due to Mutations in Solid Tumors.
Nemtsova MV et al.
Biochemistry. Biokhimiia, 2020
3D Chromosomal Landscapes in Hematopoiesis and Immunity.
Kloetgen A et al.
Trends in Immunology, 2019
EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains.
Donaldson-Collier MC et al.
Nature Genetics, 2019
Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin.
Lee CH et al.
Molecular Cell, 2018
A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
Ott HM et al.
Molecular Cancer Therapeutics, 2014
Select a paper to view details